{
    "clinical_study": {
        "@rank": "25129", 
        "arm_group": {
            "arm_group_label": "Pioglitazone 15 mg to 30 mg", 
            "description": "administered orally once daily"
        }, 
        "brief_summary": {
            "textblock": "To investigate the safety and efficacy of long-term  treatment with pioglitazone (Actos\n      tablets) in combination with biguanides (for 12 months after the start of pioglitazone\n      tablets treatment) in patients with type 2 diabetes mellitus."
        }, 
        "brief_title": "Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Biguanides / Long-term Treatment\"", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance with an observation period of 12 months designed to\n      investigate the safety and efficacy of pioglitazone (Actos) in the routine clinical setting\n      in patients with type 2 diabetes mellitus who responded inadequately to treatment with\n      biguanides in addition to diet therapy and exercise therapy (planned sample size, 1000).\n\n      The usual adult dosage is 15 to 30 mg of pioglitazone administered orally once daily before\n      or after breakfast. Dose adjustment will be made according to gender, age, and symptoms with\n      an upper limit of 45 mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with type 2 diabetes mellitus who responded inadequately to treatment with\n             biguanides in addition to diet therapy and exercise therapy\n\n          2. Patients with available HbA1c data within the 1 month prior to the start of Actos\n             Tablets treatment\n\n          3. Patients likely to be available for a 12-month observation after the start of Actos\n             Tablets treatment\n\n        Exclusion Criteria:\n\n          1. Patients who have received Actos Tablets within the past 3 months.\n\n          2. Patients who started treatment with biguanides and Actos Tablets simultaneously\n\n          3. Patients who discontinued biguanides and switched to Actos Tablets treatment.\n\n          4. Patients who received additional biguanides after the start of Actos Tablets\n             treatment\n\n          5. Patients with contraindications to Actos Tablets treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Type 2 diabetes mellitus"
            }
        }, 
        "enrollment": {
            "#text": "899", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003014", 
            "org_study_id": "237-017"
        }, 
        "intervention": {
            "arm_group_label": "Pioglitazone 15 mg to 30 mg", 
            "description": "Pioglitazone Tablets", 
            "intervention_name": "Pioglitazone", 
            "intervention_type": "Drug", 
            "other_name": "Actos"
        }, 
        "intervention_browse": {
            "mesh_term": "Pioglitazone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "December 1, 2013", 
        "number_of_groups": "1", 
        "official_title": "Actos Tablets Special Drug Use Surveillance \"Combined Use of Biguanides / Long-term Treatment\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The frequency of adverse events by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculation of summary statistics for HbA1c, fasting blood glucose, fasting immunoreactive insulin (IRI), and body weight. Calculation of homeostasis model assessment ratio (HOMA-R) and tabulation of summary statistics.", 
            "measure": "Changes in diabetes-related test values", 
            "safety_issue": "No", 
            "time_frame": "From the start to 12 months of treatment"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}